 |
30 Diseases |  |
10 Trials |
|
10 Trials |  |
301 News |  |
| «12345» |
- | Dojolvi (triheptanoin) / Ultragenyx
Trial initiation date: Compatibility of C7 With Ketogenic Diet in Patients Diagnosed With G1D (clinicaltrials.gov) - Apr 24, 2018
P1, N=15, Not yet recruiting, Sponsor: University of Texas Southwestern Medical Center
Initiation date: Apr 2018 --> Jul 2018
- | Dojolvi (triheptanoin) / Ultragenyx
Trial completion date, Trial initiation date, Trial primary completion date: Diet Treatment Glucose Transporter Type 1 Deficiency (G1D) (clinicaltrials.gov) - Mar 13, 2018
P2, N=45, Not yet recruiting, Sponsor: University of Texas Southwestern Medical Center
Initiation date: Apr 2018 --> Jul 2018 Trial completion date: Nov 2022 --> May 2023 | Initiation date: Nov 2017 --> May 2018 | Trial primary completion date: Nov 2019 --> May 2020
- | Dojolvi (triheptanoin) / Ultragenyx
Trial completion date, Trial initiation date, Trial primary completion date: Compatibility of C7 With Ketogenic Diet in Patients Diagnosed With G1D (clinicaltrials.gov) - Mar 13, 2018
P1, N=15, Not yet recruiting, Sponsor: University of Texas Southwestern Medical Center
Trial completion date: Nov 2022 --> May 2023 | Initiation date: Nov 2017 --> May 2018 | Trial primary completion date: Nov 2019 --> May 2020 Trial completion date: Nov 2022 --> Apr 2023 | Initiation date: Nov 2017 --> Apr 2018 | Trial primary completion date: Nov 2022 --> Apr 2023
- | Dojolvi (triheptanoin) / Ultragenyx
Trial completion date, Trial primary completion date: Crossover Study to Assess the Efficacy and Safety of UX007 in the Treatment of Movement Disorders Associated With Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS) (clinicaltrials.gov) - Mar 7, 2018
P3, N=40, Active, not recruiting, Sponsor: Ultragenyx Pharmaceutical Inc
Trial completion date: Nov 2022 --> Apr 2023 | Initiation date: Nov 2017 --> Apr 2018 | Trial primary completion date: Nov 2022 --> Apr 2023 Trial completion date: Dec 2019 --> Sep 2021 | Trial primary completion date: Jul 2018 --> Jul 2018
- | Dojolvi (triheptanoin) / Ultragenyx
Enrollment change, Trial completion date, Trial primary completion date: Treatment of Mitochondrial Dysfunction in Rett Syndrome With Triheptanoin (clinicaltrials.gov) - Feb 7, 2018
P2, N=12, Recruiting, Sponsor: Center for Rare Neurological Diseases, Norcross, GA
Trial completion date: Dec 2019 --> Sep 2021 | Trial primary completion date: Jul 2018 --> Jul 2018 N=10 --> 12 | Trial primary completion date: Feb 2018 --> Feb 2019 | Trial completion date: Feb 2018 --> Feb 2019
- | Dojolvi (triheptanoin) / Ultragenyx
Enrollment closed: Crossover Study to Assess the Efficacy and Safety of UX007 in the Treatment of Movement Disorders Associated With Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS) (clinicaltrials.gov) - Feb 6, 2018
P3, N=40, Active, not recruiting, Sponsor: Ultragenyx Pharmaceutical Inc
N=10 --> 12 | Trial primary completion date: Feb 2018 --> Feb 2019 | Trial completion date: Feb 2018 --> Feb 2019 Recruiting --> Active, not recruiting
- Dojolvi (triheptanoin) / Ultragenyx
Trial primary completion date: GLUT1DS: An Open-Label Trial of Triheptanoin in Patients With Glucose Transporter Type-1 Deficiency Syndrome (clinicaltrials.gov) - Jan 25, 2018
P2, N=50, Recruiting, Sponsor: Adrian Lacy
Recruiting --> Active, not recruiting Trial primary completion date: Jan 2018 --> Jan 2022
- | Dojolvi (triheptanoin) / Ultragenyx
Enrollment change, Trial primary completion date: BEAT7: Brain Energy and Aging With Triheptanoin (clinicaltrials.gov) - Dec 21, 2017
P1/2, N=15, Recruiting, Sponsor: Université de Sherbrooke
Trial primary completion date: Jan 2018 --> Jan 2022 N=26 --> 15 | Trial primary completion date: Feb 2018 --> Dec 2018
- | Dojolvi (triheptanoin) / Ultragenyx
Trial completion, Trial primary completion date: Phase 2 Study of Triheptanoin (UX007) for the Treatment of Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS) (clinicaltrials.gov) - Nov 7, 2017
P2, N=36, Completed, Sponsor: Ultragenyx Pharmaceutical Inc
N=26 --> 15 | Trial primary completion date: Feb 2018 --> Dec 2018 Active, not recruiting --> Completed | Trial primary completion date: Oct 2016 --> Sep 2017
- | Dojolvi (triheptanoin) / Ultragenyx
Trial initiation date, Trial primary completion date: Diet Treatment Glucose Transporter Type 1 Deficiency (G1D) (clinicaltrials.gov) - Oct 19, 2017
P2, N=45, Not yet recruiting, Sponsor: University of Texas Southwestern Medical Center
Active, not recruiting --> Completed | Trial primary completion date: Oct 2016 --> Sep 2017 Initiation date: Jun 2017 --> Nov 2017 | Trial primary completion date: Jun 2019 --> Nov 2019
- Dojolvi (triheptanoin) / Ultragenyx
Trial primary completion date: The Effect of Triheptanoin in Adults With McArdle Disease (Glycogen Storage Disease Type V) (clinicaltrials.gov) - Sep 1, 2017
P2, N=28, Recruiting, Sponsor: Rigshospitalet, Denmark
Initiation date: Jun 2017 --> Nov 2017 | Trial primary completion date: Jun 2019 --> Nov 2019 Trial primary completion date: Jan 2017 --> Sep 2018
- || Dojolvi (triheptanoin) / Ultragenyx
Trial primary completion date: Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD) Extension Study for Subjects Previously Enrolled in Triheptanoin Studies (clinicaltrials.gov) - May 24, 2017
P2, N=100, Enrolling by invitation, Sponsor: Ultragenyx Pharmaceutical Inc
Trial primary completion date: Jan 2017 --> Sep 2018 Trial primary completion date: Dec 2019 --> Sep 2021
- Dojolvi (triheptanoin) / Ultragenyx
Trial primary completion date: Study to Assess the Long Term Safety and Efficacy of UX007 in Participants With Glucose Type 1 Deficiency Syndrome (Glut1 DS) (clinicaltrials.gov) - Apr 19, 2017
P2, N=40, Enrolling by invitation, Sponsor: Ultragenyx Pharmaceutical Inc
Trial primary completion date: Dec 2019 --> Sep 2021 Trial primary completion date: Jul 2020 --> Sep 2018
- || Dojolvi (triheptanoin) / Ultragenyx
Trial primary completion date: Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD) Extension Study for Subjects Previously Enrolled in Triheptanoin Studies (clinicaltrials.gov) - Apr 19, 2017
P2, N=100, Enrolling by invitation, Sponsor: Ultragenyx Pharmaceutical Inc
Trial primary completion date: Jul 2020 --> Sep 2018 Trial primary completion date: Dec 2017 --> Dec 2019
- Dojolvi (triheptanoin) / Ultragenyx
Trial primary completion date: BEAT7: Brain Energy and Aging With Triheptanoin (clinicaltrials.gov) - Mar 29, 2017
P1/2, N=26, Recruiting, Sponsor: Université de Sherbrooke
Trial primary completion date: Dec 2017 --> Dec 2019 Trial primary completion date: Feb 2017 --> Feb 2018
- | Dojolvi (triheptanoin) / Ultragenyx
Enrollment open: Treatment Development of Triheptanoin (G1D) (clinicaltrials.gov) - Mar 3, 2017
P1, N=36, Recruiting, Sponsor: University of Texas Southwestern Medical Center
Trial primary completion date: Feb 2017 --> Feb 2018 Not yet recruiting --> Recruiting
- Dojolvi (triheptanoin) / Ultragenyx
New P2 trial: Open Label Trial of Triheptanoin (UX007) in Treatment of Rett Syndrome. (clinicaltrials.gov) - Feb 23, 2017
P2, N=10, Not yet recruiting, Sponsor: Sheba Medical Center
- | Dojolvi (triheptanoin) / Ultragenyx
Enrollment closed: HEMIHEP: Pilot Study, Comparative, Single-center, Randomized, Crossover, Double-blind, Against Placebo, Testing the Effectiveness of Triheptanoin Oil in Alternating Hemiplegia of Childhood (clinicaltrials.gov) - Feb 23, 2017
P2, N=10, Active, not recruiting, Sponsor: Institut National de la Santé Et de la Recherche Médicale, France
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- | Dojolvi (triheptanoin) / Ultragenyx
Enrollment open: Crossover Study to Assess the Efficacy and Safety of UX007 in the Treatment of Movement Disorders Associated With Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS) (clinicaltrials.gov) - Feb 8, 2017
P3, N=40, Recruiting, Sponsor: Ultragenyx Pharmaceutical Inc
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- | Dojolvi (triheptanoin) / Ultragenyx
Trial initiation date: Phase 2 Study of Triheptanoin (UX007) for the Treatment of Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS) (clinicaltrials.gov) - Feb 7, 2017
P2, N=40, Active, not recruiting, Sponsor: Ultragenyx Pharmaceutical Inc
Not yet recruiting --> Recruiting Initiation date: Jan 2014 --> Apr 2014
- Dojolvi (triheptanoin) / Ultragenyx
New P1 trial: Treatment Development of Triheptanoin (G1D) (clinicaltrials.gov) - Feb 2, 2017
P1, N=36, Not yet recruiting, Sponsor: University of Texas Southwestern Medical Center
- | Dojolvi (triheptanoin) / Ultragenyx
Trial completion: A Study of UX007 (Triheptanoin) in Participants With Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD) (clinicaltrials.gov) - Nov 25, 2016
P2, N=29, Completed, Sponsor: Ultragenyx Pharmaceutical Inc
Initiation date: Jan 2014 --> Apr 2014 Active, not recruiting --> Completed
- Dojolvi (triheptanoin) / Ultragenyx
New trial: Treatment With UX007 for a Single Patient With GLUT1 Deficiency Syndrome (clinicaltrials.gov) - Nov 21, 2016
P=N/A, N=1, Enrolling by invitation, Sponsor: Amy Goldstein
- ||| Dojolvi (triheptanoin) / Ultragenyx
New P3 trial: Crossover Study to Assess the Efficacy and Safety of UX007 in the Treatment of Movement Disorders Associated With Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS) (clinicaltrials.gov) - Nov 9, 2016
P3, N=40, Not yet recruiting, Sponsor: Ultragenyx Pharmaceutical Inc
- | Dojolvi (triheptanoin) / Ultragenyx
Enrollment open: BEAT7: Brain Energy and Aging With Triheptanoin (clinicaltrials.gov) - Oct 27, 2016
P1/2, N=26, Recruiting, Sponsor: Université de Sherbrooke
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- Dojolvi (triheptanoin) / Ultragenyx
New P2 trial: Triheptanoin in Mc Ardle (clinicaltrials.gov) - Sep 29, 2016
P2, N=12, Not yet recruiting, Sponsor: Institut National de la Sant
- | Dojolvi (triheptanoin) / Ultragenyx
Enrollment closed, Trial primary completion date: Phase 2 Study of Triheptanoin (UX007) for the Treatment of Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS) (clinicaltrials.gov) - Aug 8, 2016
P2, N=40, Active, not recruiting, Sponsor: Ultragenyx Pharmaceutical Inc
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2016 --> Oct 2016
- Dojolvi (triheptanoin) / Ultragenyx
Enrollment open, Trial initiation date: Treatment of Mitochondrial Dysfunction in Rett Syndrome With Triheptanoin (clinicaltrials.gov) - Jun 24, 2016
P2, N=10, Recruiting, Sponsor: Emory University
Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2016 --> Oct 2016 Not yet recruiting --> Recruiting | Initiation date: Mar 2016 --> Jun 2016
- Dojolvi (triheptanoin) / Ultragenyx
Enrollment closed: Pilot Study of Triheptanoin in Patients With Glucose Transporter 1 Deficiency Syndrome (clinicaltrials.gov) - Jun 2, 2016
P2, N=3, Active, not recruiting, Sponsor: University of British Columbia
Not yet recruiting --> Recruiting | Initiation date: Mar 2016 --> Jun 2016 Recruiting --> Active, not recruiting
- Dojolvi (triheptanoin) / Ultragenyx
New trial: TRIMI: A Pilot Trial of Triheptanoin for the Preventive Treatment of Migraine (clinicaltrials.gov) - May 27, 2016
P0, N=10, Not yet recruiting, Sponsor: University Hospital of Liege
- Dojolvi (triheptanoin) / Ultragenyx
Enrollment status: Study to Assess the Long Term Safety and Efficacy of UX007 in Participants With Glucose Type 1 Deficiency Syndrome (Glut1 DS) (clinicaltrials.gov) - May 10, 2016
P2, N=40, Enrolling by invitation, Sponsor: Ultragenyx Pharmaceutical Inc
Recruiting --> Active, not recruiting Recruiting --> Enrolling by invitation
- Dojolvi (triheptanoin) / Ultragenyx
New P2 trial: Treatment of Mitochondrial Dysfunction in Rett Syndrome With Triheptanoin (clinicaltrials.gov) - Mar 2, 2016
P2, N=10, Not yet recruiting, Sponsor: Emory University
- Dojolvi (triheptanoin) / Ultragenyx
Enrollment open: HEMIHEP: Pilot Study, Comparative, Single-center, Randomized, Crossover, Double-blind, Against Placebo, Testing the Effectiveness of Triheptanoin Oil in Alternating Hemiplegia of Childhood (clinicaltrials.gov) - Feb 27, 2016
P2, N=10, Recruiting, Sponsor: Institut National de la Santé Et de la Recherche Médicale, France
Recruiting --> Enrolling by invitation Not yet recruiting --> Recruiting
- | Dojolvi (triheptanoin) / Ultragenyx
New P1/2 trial: BEAT7: Brain Energy and Aging With Triheptanoin (clinicaltrials.gov) - Feb 10, 2016
P1/2, N=26, Not yet recruiting, Sponsor: Université de Sherbrooke
- | Dojolvi (triheptanoin) / Ultragenyx
Trial completion, Enrollment change: Triheptanoin Treatment Trial for Patients With Adult Polyglucosan Body Disease (clinicaltrials.gov) - Jan 16, 2016
P2, N=22, Completed, Sponsor: Baylor Research Institute
Not yet recruiting --> Recruiting Active, not recruiting --> Completed | N=18 --> 22
- Dojolvi (triheptanoin) / Ultragenyx
Trial primary completion date: A Study of UX007 (Triheptanoin) in Participants With Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD) (clinicaltrials.gov) - Dec 17, 2015
P2, N=30, Active, not recruiting, Sponsor: Ultragenyx Pharmaceutical Inc
Active, not recruiting --> Completed | N=18 --> 22 Trial primary completion date: Aug 2015 --> Sep 2016
- |||| Dojolvi (triheptanoin) / Ultragenyx
Enrollment open: TRIHEP3: A Comparative Phase 2 Study Assessing the Efficacy of Triheptanoin, an Anaplerotic Therapy in Huntington's Disease (clinicaltrials.gov) - Dec 16, 2015
P2, N=100, Recruiting, Sponsor: Institut National de la Santé Et de la Recherche Médicale, France
Trial primary completion date: Aug 2015 --> Sep 2016 Not yet recruiting --> Recruiting
- Dojolvi (triheptanoin) / Ultragenyx
Trial primary completion date: Pilot Study of Triheptanoin in Patients With Glucose Transporter 1 Deficiency Syndrome (clinicaltrials.gov) - Dec 4, 2015
P2, N=3, Recruiting, Sponsor: University of British Columbia
Not yet recruiting --> Recruiting Trial primary completion date: Jul 2015 --> Feb 2016
- | Dojolvi (triheptanoin) / Ultragenyx
New P2 trial: Study to Assess the Long Term Safety and Efficacy of UX007 in Participants With Glucose Type 1 Deficiency Syndrome (Glut1 DS) (clinicaltrials.gov) - Nov 9, 2015
P2, N=40, Recruiting, Sponsor: Ultragenyx Pharmaceutical Inc
- Dojolvi (triheptanoin) / Ultragenyx
New trial: Triheptanoin (UX007) to Treat Citrate Transporter Deficiency (clinicaltrials.gov) - Jul 16, 2015
P=N/A, N=0, Available, Sponsor: Irina A Anselm
- ||||| Dojolvi (triheptanoin) / Ultragenyx
New P2 trial: TRIHEP3: A Comparative Phase 2 Study Assessing the Efficacy of Triheptanoin, an Anaplerotic Therapy in Huntington's Disease (clinicaltrials.gov) - May 26, 2015
P2, N=100, Not yet recruiting, Sponsor: Institut National de la Santé Et de la Recherche Médicale, France
- Dojolvi (triheptanoin) / Ultragenyx
New P2 trial: The Effect of Triheptanoin in Adults With McArdle Disease (Glycogen Storage Disease Type V) (clinicaltrials.gov) - May 4, 2015
P2, N=28, Recruiting, Sponsor: Rigshospitalet, Denmark
- Dojolvi (triheptanoin) / Ultragenyx
Trial primary completion date: GLUT-HEP: Phase II Open Label Study Using Triheptanoin in Patients With Glucose Type 1 Transporter Deficiency GLUT1-DS (clinicaltrials.gov) - May 1, 2015
P2, N=20, Recruiting, Sponsor: Institut National de la Santé Et de la Recherche Médicale, France
Trial primary completion date: Jul 2015 --> Feb 2016 Trial primary completion date: Nov 2014 --> May 2015
- Dojolvi (triheptanoin) / Ultragenyx
Trial completion: Study of Triheptanoin for Treatment of Long-Chain Fatty Acid Oxidation Disorder (clinicaltrials.gov) - Apr 21, 2015
P2, N=32, Completed, Sponsor: Oregon Health and Science University
Trial primary completion date: Nov 2014 --> May 2015 Active, not recruiting --> Completed
- Dojolvi (triheptanoin) / Ultragenyx
New P2 trial: HEMIHEP: Pilot Study, Comparative, Single-center, Randomized, Crossover, Double-blind, Against Placebo, Testing the Effectiveness of Triheptanoin Oil in Alternating Hemiplegia of Childhood (clinicaltrials.gov) - Apr 3, 2015
P2, N=10, Not yet recruiting, Sponsor: Institut National de la Santé Et de la Recherche Médicale, France
- Dojolvi (triheptanoin) / Ultragenyx
Trial primary completion date: Phase 2 Study of Triheptanoin (UX007) for the Treatment of Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS) (clinicaltrials.gov) - Jan 28, 2015
P2, N=40, Recruiting, Sponsor: Ultragenyx Pharmaceutical Inc
Active, not recruiting --> Completed Trial primary completion date: Oct 2014 --> Jun 2016
- | Dojolvi (triheptanoin) / Ultragenyx
Enrollment closed, Trial primary completion date: A Study of UX007 (Triheptanoin) in Participants With Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD) (clinicaltrials.gov) - Jan 15, 2015
P2, N=30, Active, not recruiting, Sponsor: Ultragenyx Pharmaceutical Inc
Trial primary completion date: Oct 2014 --> Jun 2016 Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2015 --> Aug 2015
- | Dojolvi (triheptanoin) / Ultragenyx
Trial initiation date: A Study of UX007 (Triheptanoin) in Participants With Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD) (clinicaltrials.gov) - Dec 13, 2014
P2, N=30, Recruiting, Sponsor: Ultragenyx Pharmaceutical Inc
Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2015 --> Aug 2015 Initiation date: Sep 2013 --> Feb 2014
- |||| Dojolvi (triheptanoin) / Ultragenyx
Enrollment open, Trial initiation date, Trial primary completion date: Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD) Extension Study for Subjects Previously Enrolled in Triheptanoin Studies (clinicaltrials.gov) - Dec 13, 2014
P2, N=100, Enrolling by invitation, Sponsor: Ultragenyx Pharmaceutical Inc
Initiation date: Sep 2013 --> Feb 2014 Not yet recruiting --> Enrolling by invitation | Initiation date: Sep 2014 --> Dec 2014 | Trial primary completion date: Sep 2017 --> Dec 2017
- | Dojolvi (triheptanoin) / Ultragenyx
Enrollment closed: Triheptanoin Treatment Trial for Patients With Adult Polyglucosan Body Disease (clinicaltrials.gov) - Oct 30, 2014
P2, N=18, Active, not recruiting, Sponsor: Baylor Research Institute
Not yet recruiting --> Enrolling by invitation | Initiation date: Sep 2014 --> Dec 2014 | Trial primary completion date: Sep 2017 --> Dec 2017 Recruiting --> Active, not recruiting